76 completed, 16 unknown, 9 withdrawn, 6 recruiting. 115 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 115 | Completed 76, Unknown 16, Withdrawn 9, Recruiting 6, Terminated 4, Not yet recruiting 2, Active not recruiting 1, Suspended 1 |
Follow Dyskinesias: new trials by email Literature Review of Dyskinesias trials Research Report on Dyskinesias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Esketamine - Dexmedetomidine Combination Versus Dexmedetomidine Monotherapy for Hyperactive Delirium in ICU Patients on Non-Invasive Respiratory Support (SEED-NIRS Trial): Study Protocol of a Randomized Controlled Trial Esketamine combined with dexmedetomidine, Dexmedetomidine - Dexmedetomidine, Ketamine | Phase 4 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 356 | 2026-09-28 | 2026-09-03 |
| Botox Injections in Non-Cranial Nerve VII Innervated Muscles for Facial Synkinesis Botulinum Toxin Type A Injection [Botox] - Synkinesis | Phase 4 | Withdrawn | Vanderbilt University Medical Center | 2026-07-01 | 2026-11-03 | |
| Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities Deutetrabenazine Oral Capsule - Tardive Dyskinesia, Intellectual Disability | Phase 4 | Recruiting | University Hospitals Cleveland Medical Center | 25 | 2026-06-22 | 2026-07-06 |
| Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients Conversion to extended-release tacrolimus, Maintenance of immediate-release tacrolimus - Kidney Transplant Recipients, Old Age | Phase 4 | Recruiting | Massachusetts General Hospital | 92 | 2026-03-17 | 2026-05-28 |
| Efficacy of Topical Apraclonidine for the Treatment of Ocular Synkinesis Apraclonidine - Synkinesis, Facial Nerve Palsy | Phase 4 | Withdrawn | University of Alabama at Birmingham | 2025-12-01 | 2024-07-19 | |
| A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Valbenazine - Schizophrenia, Schizoaffective Disorder | Phase 4 | Recruiting | Neurocrine Biosciences | 100 | 2025-08-29 | 2026-09-18 |
| The Effects of Waning of Botulinum Toxin in the Treatment of Cervical Dystonia Botulinum toxin type A injection - Cervical Dystonia, Primary | Phase 4 | Not yet recruiting | Western University, Canada | 45 | 2025-03-30 | 2025-03-20 |
| Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities Valbenazine Oral Capsule - Tardive Dyskinesia, Intellectual Disability | Phase 4 | Withdrawn | Stephen Ruedrich | 2025-01-01 | 2024-10-24 | |
| Factors Determining the Efficacy of Botulinum Toxin for Arm Tremor in Dystonia Polymyography, Muscle ultrasound, (Functional) magnetic resonance imaging - Dystonic Tremor Syndrome | Phase 4 | Active not recruiting | Radboud University Medical Center | 60 | 2025-01-01 | 2026-08-14 |
| Effect of Dapagliflozin Administration on the Apoptosis Levels of Patients With Acute Myocardial Infarction Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia - Acute Myocardial Infarction (AMI), STEMI - ST Elevation Myocardial Infarction (MI) | Phase 4 | Completed | Yoga Yudhistira | 40 | 2024-09-21 | 2025-02-27 |
| Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China Deutetrabenazine - Huntington's Disease, Chorea | Phase 4 | Completed | Teva Branded Pharmaceutical Products R&D LLC | 50 | 2024-02-02 | 2026-08-27 |
| Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder Sublingual film containing Igalmi - Bipolar Disorder, Schizophrenia | Phase 4 | Completed | BioXcel Therapeutics Inc | 29 | 2023-10-02 | 2026-08-11 |
| Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department Sublingual film containing dexmedetomidine (BXCL501) - Agitation, Schizophrenia | Phase 4 | Withdrawn | Brigham and Women's Hospital | 2023-09-01 | 2026-01-28 | |
| Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder Dexmedetomidine, Lorazepam 2 MG/ML - Schizophrenia Agitation, Schizo Affective Disorder | Phase 4 | Unknown | Temple University | 32 | 2023-07-01 | 2023-10-23 |
| Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia Valbenazine - Schizophrenia, Schizoaffective Disorder | Phase 4 | Completed | Neurocrine Biosciences | 59 | 2023-05-09 | 2026-01-16 |
| Istradefylline Effect Protocol on Parkinson's Disease Tremor Istradefylline Pill - Parkinson Disease, Tremor | Phase 4 | Completed | Georgetown University | 27 | 2023-01-20 | 2025-03-13 |
| Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations Tacrolimus, Immediate Release, Oral, Tacrolimus Extended Release Oral Tablet - Liver Transplantation, Immunosuppression | Phase 4 | Recruiting | University of British Columbia | 124 | 2023-01-09 | 2024-01-02 |
| Nalbuphine Versus Dexmedetomidine for Prevention of Emergence Agitation in Pediatrics Nalbuphine, Dexmedetomidine, normal Saline - Agitation | Phase 4 | Unknown | Alexandria University | 126 | 2022-03-01 | 2022-04-08 |
| Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia Ingrezza Pill - Cervical Dystonia | Phase 4 | Completed | The Orthopedic Foundation | 20 | 2021-10-19 | 2023-10-06 |
| Emergence Agitation After Nasal Surgery: a Randomized Controlled Comparison Between Melatonin and Mirtazapine Mirtazapine, Melatonin, Placebo - Agitation | Phase 4 | Completed | Ain Shams University | 165 | 2021-06-15 | 2022-04-15 |
Showing 20 of 115. Sign in to see all of them.
Psychomotor Agitation (48) · Psychotic Disorders (14) · Tardive Dyskinesia (13) · Schizophrenia (12) · Torticollis (12) · Parkinson Disease (10) · Tremor (10) · Dystonia (9) · Alzheimer Disease (7) · Bipolar Disorder (7) · Dementia (6) · Aggression (4) · Delirium (4) · Huntington Disease (4)
Neurologic Manifestations (112) · Pathological Conditions, Signs and Symptoms (111) · Signs and Symptoms (110) · Nervous System Diseases (105) · Neurobehavioral Manifestations (51) · Behavior (50) · Behavioral Symptoms (50) · Aberrant Motor Behavior in Dementia (48) · Central Nervous System Diseases (48) · Psychomotor Disorders (48) · Mental Disorders (40) · Brain Diseases (33) · Movement Disorders (33) · Neurodegenerative Diseases (27)
Dexmedetomidine (14) · Botulinum Toxins, Type A (13) · Saline Solution (8) · Risperidone (7) · Haloperidol (6) · abobotulinumtoxinA (6) · valbenazine (6) · Olanzapine (5) · Quetiapine Fumarate (5) · incobotulinumtoxinA (4) · Amantadine (3) · Clonidine (3) · Levetiracetam (3) · Lorazepam (3) · Memantine (3)
Neurocrine Biosciences (4) · Allergan (3) · Seoul National University Hospital (3) · Ain Shams University (2) · Merz Pharmaceuticals GmbH (2) · New York State Psychiatric Institute (2) · Tang-Du Hospital (2) · Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan (2) · University of South Florida (2) · Abarbanel Mental Health Center (1) · Ajou University School of Medicine (1) · Alexandria University (1) · Assistance Publique - Hôpitaux de Paris (1) · Aziende Chimiche Riunite Angelini Francesco S.p.A (1) · Beijing Pins Medical Co., Ltd (1)
United States (51) · China (7) · South Korea (7) · Germany (5) · France (4) · Taiwan (4) · Turkey (Türkiye) (4) · Austria (3) · Canada (3) · Egypt (3) · Puerto Rico (3) · United Kingdom (3) · Argentina (2) · Australia (2) · Croatia (2)
Harvey S Singer, MD (2) · Stanley N Caroff, MD (2) · Stephen Ruedrich, MD (2) · Theresa A Zesiewicz, MD (2) · Adrian Leibovici MD (1) · AhYoung Oh (1) · Ahmad Yasa MD (1) · Alaa Elkateb, MD (1) · Alberto Espay, MD (1) · Alexander Storch, M (1) · Ali Fuat Erdem, Professor (1) · Andrea Snow, PhD MS BS (1)
PMID 11442853, PMID 11812709, PMID 12635389, PMID 12768180, PMID 16247923, PMID 17093249, PMID 17388711, PMID 18433676, PMID 20418301, PMID 20441726, PMID 20705788, PMID 21476613, PMID 21845596, PMID 22550086, PMID 22567095, PMID 23075176, PMID 23123071, PMID 23422376, PMID 23687362, PMID 24606117, PMID 25230144, PMID 25476727, PMID 26332857, PMID 27264945, PMID 27622717, PMID 27855483, PMID 28877705, PMID 28973094, PMID 29249041, PMID 29881956, PMID 30169192, PMID 30282677, PMID 30323563, PMID 31111094, PMID 32528650, PMID 33324891, PMID 34627829, PMID 35330880, PMID 37205243
2005 (1), 2009 (1), 2016 (1), R01AG021488 (1), R01MH055735 (1), R01NS073683 (1), R34MH085844 (1)